Literature DB >> 34897941

Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.

Jochen Seufert1, Stefanie Lanzinger2,3, Thomas Danne4, Peter Bramlage5, Sebastian M Schmid3,6, Florian Kopp7, Stephan Kress8, Peter Fasching9, Claus Schäfer10, Reinhard W Holl2,3.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitor; antidiabetic drug; population study; primary care; type 1 diabetes

Mesh：

Substances：

Year:  2021        PMID： 34897941     DOI： 10.1111/dom.14620

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  2 in total

1.  Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus.

Authors:  Camila Moreno Rosa; Dijon Henrique Salome Campos; David Rafael Abreu Reyes; Felipe Cesar Damatto; Lucas Yamada Kurosaki; Luana Urbano Pagan; Mariana Janini Gomes; Camila Renata Corrêa; Ana Angelica Henrique Fernandes; Marina Politi Okoshi; Katashi Okoshi
Journal:  Antioxidants (Basel)       Date:  2022-05-17

2.  Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?

Authors:  Jennifer R Snaith; Jerry R Greenfield
Journal:  Med J Aust       Date:  2022-06-30       Impact factor: 12.776
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.